AGEN Shares Outstanding History



Below is a table of the AGEN shares outstanding history going back to 10/3/2011:

Date AGEN Shares Outstanding
10/3/201119.39M
11/2/201121.86M
2/24/201222.92M
5/4/201223.22M
8/3/201224.93M
11/2/201225.06M
2/22/201325.78M
5/9/201328.84M
8/5/201330.31M
11/4/201336.15M
2/24/201463.35M
4/30/201463.42M
7/28/201463.87M
10/27/201463.88M
2/24/201572.10M
4/27/201572.84M
7/24/201585.91M
10/30/201586.25M
2/29/201688.16M
5/2/201688.53M
7/29/201688.65M
11/2/201688.78M
2/28/2017100.20M
4/26/2017101.00M
7/31/2017101.61M
11/2/2017102.09M
2/28/2018104.51M
5/4/2018105.98M
8/3/2018115.43M
11/2/2018122.26M
3/11/2019136.76M
5/6/2019136.81M
8/5/2019139.92M
12/31/20182.29M
11/1/2019139.97M
3/12/2020164.66M
5/7/2020173.00M
3/15/2021208.57M
1/31/2022262.04M
8/4/2022288.54M
11/4/2022310.60M
3/15/2023338.83M
5/5/2023348.88M
8/4/2023379.57M
11/3/2023381.50M

Also see: AGEN Market Cap History
AGEN YTD Return
AGEN Historical Shares Outstanding:
+27.93% CAGR
AGEN Historical Shares Outstanding: +27.93% CAGR

Mouse over chart for data details
10/3/2011 ...11/3/2023
Agenus is a clinical-stage immuno-oncology (I-O) company engaged in the development of a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer and infections. Co.'s antibody candidates are balstilimab (an anti-PD-1 antibody) and zalifrelimab (an anti-CTLA-4 antibody), which are in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Co. is also developing an anti-CTLA-4 antibody, botensilimab (also known as AGEN1181), which is designed to improve the magnitude of responses to first-generation anti-CTLA-4 molecules. We show 45 historical shares outstanding datapoints in our coverage of AGEN's shares outstanding history.

Understanding the changing numbers of AGEN shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like AGEN versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching AGEN by allowing them to research AGEN shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree AGEN Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Agenus (AGEN) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

AGIO Shares Outstanding History
AGL Shares Outstanding History
AGLE Shares Outstanding History
AGN Shares Outstanding History
AGRX Shares Outstanding History
AGTC Shares Outstanding History
AGTI Shares Outstanding History
AHCO Shares Outstanding History
AHPI Shares Outstanding History
AIKI Shares Outstanding History
More Healthcare companies »

 

AGEN Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2024, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 9.5%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 9.5%.